Comparing Osimertinib-Based Frontline Combination Regimens in EGFR-Mutant NSCLC

This segment compares the currently available frontline combination treatment options for EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing the importance of individualized treatment selection. Drs. Mark Socinski and Susan Scott discuss the lack of direct efficacy data demonstrating superiority of one combination regimen over another, noting that treatment decisions are primarily driven by differences in administration, toxicity profiles, and patient preferences. Dr. Scott contrasts FLAURA2 (osimertinib plus chemotherapy) with MARIPOSA (amivantamab plus lazertinib), reviewing practical considerations such as infusion schedules, clinic visit frequency, cutaneous toxicities, chemotherapy-related adverse effects, anticoagulation requirements, and supportive care strategies, including prophylactic management of skin toxicities. Dr. Socinski highlights the potential convenience of completing chemotherapy after a finite duration in the FLAURA2 regimen while maintaining long-term clinical benefit. Together, they underscore the value of shared decision-making to align treatment selection with each patient's clinical characteristics, lifestyle, and preferences.